Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01090921 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
A Phase 2 study, sponsored by Boston VA Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01090921 is a Phase 2 study that has completed, run by Boston VA Research Institute. The registered enrollment target is 50 participants.
The verdict
NCT01090921, a Phase 2 study, has completed, sponsored by Boston VA Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a research study to see if a new drug called bortezomib is useful to treat multiple myeloma in people who are newly diagnosed, and have not yet received treatment for their disease. VELCADE® (bortezomib) for Injection is a drug under development by Millennium Pharmaceuticals, Inc.
Interventions
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-05 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01090921
The ClinicalTrials.gov registry entry for NCT01090921 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston VA Research Institute, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bortezomib is the first listed.
NCT01090921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01090921 about?
NCT01090921 is a clinical study titled "Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma". This is a research study to see if a new drug called bortezomib is useful to treat multiple myeloma in people who are newly diagnosed, and have not yet received treatment for their disease. VELCADE® (bortezomib) for Injection is a drug under development by Millennium Pharmaceuticals, Inc.
What is the current status of trial NCT01090921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2007-05. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01090921?
The interventions under investigation include: Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01090921?
This trial is sponsored by Boston VA Research Institute, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.